BioLineRx (NASDAQ:BLRX) Announces Earnings Results

BioLineRx (NASDAQ:BLRX – Get Rating) posted its earnings results on Wednesday. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01), Zacks reports. During the same quarter in the previous year, the business earned ($0.10) EPS.

BioLineRx Price Performance

Shares of NASDAQ:BLRX traded down $0.15 during trading on Friday, reaching $1.40. The company had a trading volume of 363,120 shares, compared to its average volume of 405,769. The firm’s fifty day moving average is $1.12 and its 200 day moving average is $0.81. The firm has a market capitalization of $86.11 million, a PE ratio of -2.82 and a beta of 1.89. BioLineRx has a twelve month low of $0.55 and a twelve month high of $1.98. The company has a debt-to-equity ratio of 0.17, a quick ratio of 4.87 and a current ratio of 4.87.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on BLRX shares. StockNews.com started coverage on shares of BioLineRx in a research note on Thursday, May 18th. They set a “sell” rating for the company. HC Wainwright reissued a “buy” rating on shares of BioLineRx in a research note on Wednesday, March 22nd.

Institutional Trading of BioLineRx

Institutional investors have recently made changes to their positions in the stock. Atria Wealth Solutions Inc. acquired a new stake in shares of BioLineRx in the 1st quarter worth approximately $178,000. Renaissance Technologies LLC lifted its stake in shares of BioLineRx by 278.0% in the 4th quarter. Renaissance Technologies LLC now owns 257,900 shares of the biotechnology company’s stock worth $152,000 after acquiring an additional 189,678 shares during the period. Envestnet Asset Management Inc. acquired a new stake in shares of BioLineRx in the 1st quarter worth approximately $88,000. Finally, LPL Financial LLC lifted its stake in shares of BioLineRx by 152.7% in the 4th quarter. LPL Financial LLC now owns 117,710 shares of the biotechnology company’s stock worth $69,000 after acquiring an additional 71,134 shares during the period. 18.15% of the stock is owned by institutional investors and hedge funds.

BioLineRx Company Profile

(Get Rating)

BioLineRx Ltd. is a clinical stage biopharmaceutical company, which engages in the research and development of treatments that focus on cancer. Its product pipeline includes Motaxafortide (BL-8040), which is used for stem-cell mobilization, solid tumors, and acute myeloid lukemia; and AGI-134, which is an immunotherapy treatment used for multiple solid tumors.